# INTERCEPT Blood System Platelet Processing and ILLUMINATOR Service Maintenance Canonical: https://abierto.us/opportunities/ht941025n0005 - Solicitation number: HT941025N0005 - Notice type: Combined synopsis and solicitation - Status: Awarded to Cerus Corporation - Department: Department of Defense - Agency: Defense Health Agency (Dha) - Contracting office: Defense Health Agency HCD West (HT9410) - NAICS: 325413 In-Vitro Diagnostic Substance Manufacturing - Product or service code: 6550 In Vitro Diagnostic Substances, Reagents, Test Kits and Sets - Place of performance: Agana Heights, Guam - County: Guam (FIPS 66010). https://abierto.us/counties/guam-gu-66010 - First posted: October 18, 2024 - Last posted: October 18, 2024 - SAM.gov: https://sam.gov/workspace/contract/opp/6bd5c245dc3548549ffe1f77c7b7395e/view ## Description THIS IS A NOTICE OF INTENT TO AWARD A SOLE SOURCE SUPPLY CONTRACT AND IS NOT A REQUEST FOR COMPETITIVE QUOTES. The Defense Health Agency Contracting Activity (DHACA), Western Markets Contracting Division (WMCD), San Diego, intends to award a firm fixed price contract for INTERCEPT Platelet Small Volume Processing Set, INTERCEPT Platelet Processing Set with Dual Storage Containers, and Annual Maintenance for Illuminator Serial Numbers V02081701 and V0281702 in support of Blood Bank Department, Naval Hospital Guam in accordance with Federal Acquisition Regulation FAR 13.106-1(b)(1)(i), only one source being available to meet the Government’s needs, to: **Cerus Corporation Unique Entity ID:** **KJJQRRLY2FL5 CAGE:** 1PVJ6 1220 Concord Ave., Ste 600 Concord, CA 94520-4906 Period of Performance: **Base:** **12/1/2024 – 11/30/2025 Option 1:** **12/1/2025 – 11/30/2026 Option 2:** 12/1/2026 – 11/30/2027 Cerus Corporation is a leading biotechnology company specializing in pathogen reduction technology for blood products. Their INTERCEPT Blood System is FDA approved for use with apheresis platelets and whole blood-derived plasma, significantly reducing the risk of transfusion-transmitted infections (TTIs) and sepsis. The system allows for the production of therapeutic platelet doses and plasma units, enhancing blood safety. Cerus Corporation holds exclusive licensing agreements and has a proven track record of providing highly specialized services that are critical for maintaining blood safety standards. Their unique qualifications make them the ideal choice for fulfilling the contract requirements. This notice of intent is not a request for competitive proposals, and no solicitation document exists for this requirement. Sources interested in responding to this notice are required to submit a capability statement that includes management and technical data and cost information, in sufficient detail and with convincing evidence that clearly demonstrates the capability to provide the required product for United States Naval Hospital Guam. Capability statements shall not exceed six (8.5 x 11 inch) pages using a font size no smaller than 10-point. All capability statements received by the due date of this notice will be considered by the Government. A request for documentation or additional information or submissions that only ask questions will not be considered as an affirmative response. A determination by the Government not to compete based on responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement or to proceed with a sole source purchase order. If a vendor challenges the basis of this requirement, please email capability statements as a Microsoft Word or Adobe PDF attachment to Merlinda M. Labaco at Merlinda.m.labaco.civ@health.mil. The closing date for challenges is no later than 1:00 pm Pacific Daylight Time, 4 November 2024. NO TELEPHONE REQUESTS/OFFERS WILL BE HONORED ## Award on USAspending - Recipient: Cerus Corporation (UEI KJJQRRLY2FL5) - Contract: HT941025P0011, purchase order - Obligated: $128,498.00 - Competition: Not Competed Under SAP, 1 offers received - Link: solicitation number HT941025N0005 equals the FPDS solicitation identifier; same awarding office HT9410 (high confidence) - Record: https://www.usaspending.gov/award/CONT_AWD_HT941025P0011_9700_-NONE-_-NONE-/ ## Publications - October 18, 2024: Combined synopsis and solicitation, due November 4, 2024 at 4:00 PM EST. Notice 6bd5c245dc3548549ffe1f77c7b7395e. https://sam.gov/workspace/contract/opp/6bd5c245dc3548549ffe1f77c7b7395e/view ## Points of contact - Merlinda Labaco, merlinda.m.labaco.civ@health.mil - Uyen Tran, uyen.t.tran6.civ@health.mil --- Source: SAM.gov Contract Opportunities bulk extract and USAspending.gov award data. Confirm deadlines on SAM.gov before responding. Cite https://abierto.us/opportunities/ht941025n0005.